Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Hypercholesterolemia or Mixed Dyslipidemia
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Hypercholesterolemia
- Mixed Dyslipidemia
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This non-interventional study will be conducted to characterize the risks and benefits of bempedoic acid and/or its fixed-dose combination with ezetimibe in a real-world clinical setting in adult patients with hypercholesterolaemia or mixed dyslipidaemia and to gain insight into the effectiveness (m...
This non-interventional study will be conducted to characterize the risks and benefits of bempedoic acid and/or its fixed-dose combination with ezetimibe in a real-world clinical setting in adult patients with hypercholesterolaemia or mixed dyslipidaemia and to gain insight into the effectiveness (managing plasma levels of low-density lipoprotein cholesterol) as well as safety (clinical events associated with the treatment modalities). Real world evidence will be collected in 8000 participants, treated by specialized as well as non-specialized physicians in hospitals and office based centers.
Tracking Information
- NCT #
- NCT04579367
- Collaborators
- Not Provided
- Investigators
- Study Director: Global Clinical Leader Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Get Well Soon